Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program

Pas encore traduit Pas encore traduit
Catégorie Primary study
JournalBlood
Year 2012

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
  • EINSTEIN PE [Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism] (12 documents)
This article is part of the following matrixes of evidence:
Loading references information
Cet article n'a pas de résumé
Epistemonikos ID: 13b906794177a34713e2cb43ca3e0c7093cddb81
First added on: May 17, 2016